Summary Significant low density lipoprotein (LDL) uptake by tumour cells led to the use of LDL as a discriminatory vehicle for the delivery of cytotoxic drugs. In the current study, the lipophilic elliptinium derivative, elliptinium-oleate (OL-NME), was incorporated into LDL to reach an incorporation level of 400 molecules per LDL particle. The OL-NME-LDL complex showed cytotoxic effects on normal human fibroblasts while the cytotoxicity was not observed on receptor-defective human fibroblasts, indicating the ability of the complex to be preferentially metabolised by the LDL receptor. In vivo metabolism of the complex was related to the LDL receptor pathway. The metabolic clearance was the same for native LDL (17.1 ml h-') and OL-NME-LDL complex (16.2 ml h'). LDL incorporated OL-NME enhanced the antitumour activity against murine B16 melanoma model; this resulted from increased efficacy for OL-NME-LDL at doses equal to free 9-OH-NME (157 vs 76 of Increase Life Span (ILS) (%) values after intraperitoneal (i.p.) drug injection on i.p. implanted tumour model and 45 vs -2 ILS (%) values after intravenous drug injection on subcutaneous implanted tumour model). These data suggest that LDL improves the potency of lipophilic cytotoxic drugs against tumours that express LDL receptor activity.
Cells may obtain cholesterol in two ways: by endogenous synthesis from Acyl-CoA or by uptake of cholesterolcontaining particles, lipoproteins, from their environment. The most important lipoprotein in this regard is LDL, the major cholesterol-carrying particle in human plasma. LDL consists of an apolar core of cholesteryl esters and triglycerides surrounded by a phospholipid monolayer containing free cholesterol and Apolipoprotein B (Apo B) (Gotto et al., 1986 ). This protein is responsible for recognition of a cell-specific high-affinity receptor, so called LDL receptor. Following binding to these receptors, located on coated pits on the cell surface, the LDL is internalised and degraded in lysosomes with subsequent release of the cholesterol for use in the cell (Goldstein & Brown, 1977) .
Many years ago, LDL was proposed as a useful discriminatory vehicle for the delivery of cytotoxic drugs to tumour cells on the basis of a higher uptake of LDL by these tissues (Gal et al., 1981) . Some cancer cells, which proliferate rapidly, need large amounts of cholesterol for new membrane synthesis. A logical consequence could be that cancer cells will have LDL receptor activity higher than normal cells (Hynds et al., 1984; Vitols et al., 1985; Vitols et al., 1990a; Rudling et al., 1990) . However, the increased LDL uptake by tumour cells is still unexplained: a high cholesterol demand for cell growth or a mechanism related to cell transformation. Recent data suggest that a mechanism involving growth factors could be of importance in the regulation of the expression of the LDL receptor gene (Mazzone et al., 1990) .
LDL presents many other advantages as drug carriers that may circumvent a lot of problems encountered with synthetic carriers: (1) LDL may be an interesting delivery system to administer highly lipophilic compounds with promising cytotoxic effect in vitro which have never reached clinical trials because of difficulties in finding a suitable drug carrier (Vitols et al., 1990b; Lestavel-Delattre et al., 1992) . On the other hand, drug sequestration in the core space provides protection from serum enzyme and water. (2) LDL, which is a physiological carrier, is not cleared by the reticuloendothelial system and may prolong the serum half-life of antineoplastic drugs by incorporation into it (De Smidt & Van Berkel, 1990 (Iwanik et al., 1984) .
We have reported the incorporation of esters of elliptinium with fatty acids, a series of lipophilic derivatives of ellipticine, into the LDL (Samadi-Baboli et al., 1990) . Elliptinium acetate is an anti-neoplastic agent derived from ellipticine which is currently used in the treatment of metastatic breast cancer (Paoletti et al., 1980; Auclair et al., 1987) . The incorporation of the lipophilic derivative was performed by a technique which consisted of a fusion of micro emulsion containing drug with LDL (Samadi-Baboli et al., 1989 ).
Among the derivatives tested, oleate of elliptinium (OL-NME) showed the most potent incorporation. The drug-LDL complexes were able to recognise the LDL receptor in fibroblast, but not the 'scavenger receptor' (Kodama et al., 1990) of mouse peritoneal macrophages. On the other hand, the complex exerted a higher cytotoxic efficacy than free drug, in vitro, on L1210 cells. The incorporation rate of OL-NME into LDL has limited the investigations in vivo. We describe, in this paper, modifications of the incorporation technique which lead to a higher OL-NME incorporation level into LDL without affecting the recognition of the complex by the LDL receptor in vitro and in vivo. The antitumour activities of the drug-LDL against the B16 melanoma solid tumour in mice were evaluated with the OL-NME-LDL complex to show its potential in the treatment of tumours.
Materials and methods

Materials
Sodium, 1251 and "'I (carrier free, pH = 7-11) were obtained from Amersham France (Les Ullis, France). Cholesteryloleate, dimirystoylphosphatidyl choline (DMPC), phosphatidylserine (PS), sphingomyelin and cholesterol were purchased from Sigma (France) and were judged 99% pure and used without further purification. 9-Hydroxy-N2-methyl ellipticinium acetate (9-OH-NME) was kindly provided by Sanofi Group (France). 9-Oleyloxy-hydroxy-N2-methyl ellipticinium oleate (OL-NME) was synthesised as described by Samadi-Baboli et al. (1990 Incorporation of OL-NME into LDL The method recently described (Samadi-Baboli et al., 1990) using the fusion technique between drug-containing micro emulsions and LDL was used with modifications. Lipids were weighed out to give the desired ratio of the six components (OL-NME/TG/PC/Sphin/Ch/PS) and dissolved in chloroform. The solvent was removed by evaporation under a stream of N2 followed by vacuum dessication at 10°C for 12 to 16 h. The dry lipids were resuspended in 1 ml of dry isopropanol. The drug-containing micro emulsions were prepared by injection of lipid components in a dry isopropanol solution into a rapidly vortexing solution of phosphate buffer with the entire system kept at 51°C throughout the procedure.
The micro emulsions were incubated with LDL in the presence or absence of bovine serum albumin (BSA) (5 mg ml-') for 20 h at 37°C (the extent of transfer did not increase greatly with incubation times longer than 20 h). Drug-LDL (d = 1.02-1.062) was separated from the micro emulsion by ultracentrifugal flotation, in KBr density gradient using a vertical ultracentrifugation rotor (VTi-50, Beckman-France) (Paumay et al., 1985) . After the separation, two bands were noticed. Micro emulsions bands in the 1.006-1.019 g ml-' density range, drug-LDL in the 1.02-1.062 g ml-' density range. The band of drug-LDL was drawn off, purified by a second ultracentrifugation step in KBr at a density of 1.062 and subjected to extensive dialysis for 24 h against LDL buffer to remove KBr, sterilised by filtration through a 0.45 ltm pore size filter and stored at 4°C (up to 2 weeks). The OL-NME-LDL complex was then passed through a Sephadex G25 PD-10 column (Pharmacia, France) to remove any non incorporated metabolites of the drug. More than 98% of the drug remained associated within the LDL complex. The purity of the OL-NME-LDL complex was assayed by agarose gel electrophoresis and by immunohistochemical analysis. The drug-LDL complex (as well as native LDL) migrated as a single band with ,B mobility and did not react significantly with anti-BSA antisera (Sigma, France). The immunoreactivity against anti-apolipoprotein B was similar to that observed with native LDL. The particle size of native LDL and drug-LDL complex was determined as previously described (Samadi-Baboli et al., 1990) by laser light scattering (Nanosizer, Coultronics, Margenty, France). The size distribution was of 25 ± 6 nm for the complex and 22 ± 7 nm for native LDL.
HPLC assay of elliptinium-oleate (OL-NME) The OL-NME and 9-OH-NME concentrations were measured by HPLC analysis as previously described (SamadiBaboli et al., 1990 ). An aliquot (200 gl) of drug-LDL complex and native LDL were spiked with 25 Ll of N2-propyl-9-hydroxy-ellipticinium (9-OH-NPE), used as internal standard (final concentration 1.25 tig ml-'). All the drug and internal standard were extracted twice with ethylacetate (2 x 1 ml) after the addition of 100 Ll of ammonium hexafluorophosphate (final concentration 250 mM) as counterion and (2 x 3 ml) acetate buffer 0.5 M, pH = 5.5. The mixture was centrifuged twice at 2000 r.p.m. for 10 min. The organic phase was drawn off and dried under a stream of nitrogen. The residue was redissolved in 200 il of the mobile phase (methanol-water 75:25 with 5 mM acetate buffer adjusted to pH 5.5 with glacial acetic acid). A Waters CN tiBondapak reverse-phase column (30 x 3.9 mm i.d.) was used. The assay was carried out at 313 nm. This technique allowed the quantitative determination of the two drugs, OL-NME and 9-OH-NME.
Study of the stability of the drug-LDL complex in vitro Stability of OL-NME-LDL was tested by incubation in human plasma. One ml of complex (507 pg OL-NME mg' Apo B) was mixed with 5 ml of human plasma. The mixture was incubated at 37°C. After 24 and 48 h of incubation, 3 ml aliquots were removed from the mixture, followed by sequential preparative ultracentrifugation in order to separate the different lipoprotein species (Havel et al., 1955) . The lipoprotein fractions and the lipoprotein deficient fraction were separated and analysed for OL-NME and 9-OH-NME content by HPLC.
Chemical modification and labelling of native LDL and OL-NME-LDL The LDL were iodinated (1251 and '3'I) by the iodine monochloride method of Mac Farlane modified by Bilheimer et al. (1972) . The labelled lipoproteins were then freed of unbound radioiodide and glycine buffer by exhaustive dialysis against 0.15 M NaCI/0.01% Na2EDTA, pH 7, followed by gel filtration through Sephadex G25 PD-10 column (Pharmacia, France). The {f31I-LDL} were treated with 1,2-cyclohexanedione as described elsewhere (Shepherd et al., 1979; Mahley et al., 1977) , to block the charge on the arginyl residues of its protein moiety. Cyclohexanedione-modified LDL (CHD-LDL) prepared in this way has been fully characterised previously (Slater et al., 1982) . '25I-OL-NME-LDL and '31I-CHD-OL-NME-LDL complexes were obtained by incorporation of the OL-NME into labelled and/or chemically modified LDL as described above in Materials and methods.
The specific activities of the different preparations were '251-LDL: 210c.p.m. ng-' protein, 1251-OL-NME-LDL: 161 c.p.m. ng-' protein, '3II-CHD-LDL: 155 c.p.m. ng-' protein, '1I-CHD-OL-NME-LDL: 74 c.p.m. ng-' protein.
LDL turnover protocol in vivo and data analysis Two-month-old male New Zealand white rabbits (Institut National de la Recherche Agronomique, INRA, Toulouse, France), maintained ad libitum on a commercially available diet were used in the turnover study. Two days prior to and throughout each turnover study, the rabbits were given 0.1 g 1-' of KI in their drinking water to prevent thyroidal sequestration of radioiodide. Approximately 10 LCi each of LDL and cyclohexandione-treated LDL (CHD-LDL) labelled with different isotopes of iodine were mixed, sterilised by membrane filtration (0.45 emulsions. The result suggests that these compounds are assumed to be important in maintaining lipid particle integrity. All the drug not incorporated into lipoproteins was quantitatively recovered in the micro emulsion layer after density gradient ultracentrifugation. The chemical composition of the micro emulsions had an important effect on the drug incorporation level. Micro emulsions that contained triglyceride (assay 4) were more effective than those that contained cholesteryl oleate (assay 2) (120 ± 12 vs 88 ± 8). The fatty acid moiety of the triglyceride in the OL-NME-rich micro emulsion significantly influenced the extent of incorporation into LDL. Micro emulsions that contained triacetate (62 ± 1.5) were about one-half as effective as those that contained triolein (120 ± 12). Albumin seems to be an important factor in maintaining particle integrity and might involve fusion (Parks et al., 1985) . Addition of albumin (assay 6-8) to an incubation mixture stimulated the incorporation of OL-NME. Thus, the ratios between the different components of the micro emulsion and the components of the incubation mixture influence the incorporation rate of the drug into LDL; the optimal conditions are presented in assay 8. The OL-NME concentration in LDL complexes was measured by HPLC analysis. The ratio of OL-NME/protein for six preparations (assay 8) was 480 ± 7 tg OL-NME mgof protein corresponding to an average of about 400 molecules of OL-NME incorporated by LDL particles (assuming 514 kDa for Apolipoprotein B molecular weight). Under these conditions, the recovery of OL-NME in LDL was 28 ± 2% of that originally present in the OL-NME-rich micro emulsion. All the following experiments were conducted with the complex prepared using condition 8 of Table   I .
Stability of the drug-LDL complex in serum
In order to study the stability of OL-NME-LDL particles in human plasma and the possible transfer of the drug to other lipoprotein classes, the preparation of the OL-NME-LDL was incubated at 37°C for 48 h in human plasma. Then, the lipoprotein fractions were separated by density gradient ultracentrifugation and analysed for OL-NME content. The results are presented in Table II . About 5% of the 9-OH-NME, the product of OL-NME hydrolysis, appeared in the solution after 24 h or 48 h of incubation in plasma at 37°C. More than 80% of the OL-NME was recovered in LDL. About 10% of the OL-NME was detected in other lipoprotein fractions, principally in the VLDL fraction. Drug was not recovered within the LPDS in significant amounts.
Cytotoxic activity of the OL-NME-LDL complex To determine whether the cytotoxic effect of the drug-LDL complex is dependent on the LDL receptor activity, increasing concentrations of OL-NME-LDL complexes were incubated with normal and totally LDL-receptor defective fibroblasts. As shown in Figure la , the drug-LDL complex preserved a cytotoxic activity when incubated with the receptor-positive fibroblasts, while no effect was observed with the receptor-defective fibroblasts; the low effect observed Table II Stability of OL-NME-LDL within plasma. One ml of OL-NME-LDL (507 jg of OL-NME/mg of Apolipoprotein B) was incubated in 5 ml ofhuman plasma. At the indicated time, aliquots were removed. The lipoprotein fractions were separated by ultra centrifugation and analysed for OL-NME and 9-OH-NME content by HPLC as described under Materials 9-OH-NME (M) Figure 1 Comparison between OL-NME-LDL complex (a) and 9-OH-NME (b) cytotoxic activity on normal (U) and totally LDL receptor defective (0) human fibroblasts. The survival fraction (%) was measured as described in Materials and methods. Drug concentrations are expressed in terms of 9-OH-NME concentration in the culture medium. Each point shows the mean of two experiments.
for the higher complex concentration was probably due to unspecific bulk endocytosis. Free 9-OH-NME presented similar cytotoxic effects against the two cell types (Figure lb ).
9-OH-NME was taken as a control since we previously demonstrated that free OL-NME has little effect on the cellular cytotoxicity (Samadi-Baboli et al., 1990) .
Turnover study The decay of plasma radioactivity was almost identical for native LDL and OL-NME-LDL (Figure 2 ). Cyclohexanedione modification of human LDL or OL-NME-LDL complexes delayed its clearance from the plasma of rabbits (10.8 ml h-1 vs 17.1 ml h-' for native LDL and 8.75 ml h' vs 16.2 ml h' for drug-LDL complexes). On the assumption that the removal rate of the modified lipoprotein represents receptor-independent catabolism, the difference between this value and the fractional clearance rate of untreated LDL is a measure of receptor-mediated catabolism. Receptor-mediated clearance accounted for 37% and 45% for native and OL-NME-LDL complexes receptively. The total fractional catabolic rate, which measures the fraction of the intravascular pool of LDL catabolised per day, was 1.80 ± 0.09 pool/day (mean ± s.d.) when rabbits were given an injection of native LDL. Similar mean values for total (1.70 ± 0.06 pool/day) and receptor-independent fractional catabolic rate (1.05 ± 0.04 pool/day) were obtained when other rabbits were given an injection of OL-NME-LDL.
In vivo antitumour activity It would be suitable to compare the therapeutic and toxic effects of OL-NME in the free form and in LDL complex. LDL incorporated OL-NME in rabbits. Human "'5l-LDL (0) and "'I-CHD-LDL (A) or '25I-OL-NME-LDL (U) and 131I-CHD-OL-NME-LDL (A) were injected intravenously in series of three rabbits as described under Materials and methods. Plasma samples were removed at the indicated time and the % of injected dose remaining was plotted in a semi-logarithmic fashion. Each point is the mean of the three rabbit experiments. The variation was less than 10% of the mean.
However, this cannot be easily done since this drug is water insoluble. Nevertheless, we compared the efficiency of the OL-NME-LDL complex with free 9-OH-NME, the cytotoxic drug currently used in human therapy. However, the antitumour activity of OL-NME was tested, dissolved in the stabilised micro emulsion. The efficacy of free 9-OH-NME and LDL-incorporated OL-NME was investigated first in the B16 melanoma ascite tumour model after intraperitoneal injection (i.p.) of the drugs (Table III) . Administration of LDL-incorporated OL-NME-LDL resulted in a significant increase in antitumour activity at the same dose as compared with the free 9-OH-NME or with OL-NME incorporated into micro emulsions. Fractional administration of the same total dose in two and three injections per day led to a larger increase in the antitumour activity of the OL-NME-LDL complex (ILS (%) values of 140 and 157 vs 67 and 76 for free 9-OH-NME). The LDL/free median survival times of 1.31 and 1.30 indicated that OL-NME encapsulated in LDL is more efficient than free drug at an equal dose. Multiple dose treatment schedules of OL-NME-LDL increased the number of long-surviving mice. Ten per cent of the mice survived for 60 days for a total drug dose of 9 mg kg-' (administered in 9 days twice or three times a day). Long term survival was not observed at any dose or schedule with free 9-OH-NME. No changes in body weight has been noted in any lot of mice, whatever the treatment. Table III Antitumoral activity offree 9-OH-NME and OL-NME-LDL complex in intraperitoneal Melanoma B16 bearing CD57BL/6J mice. Mice were given injection i.p. of the indicated samples 24 h post i.p. injection of the Melanoma B16 tumour. OL-NME was incorporated in the LDL and the micro emulsions as described under Materials and methods. Drug doses are expressed in term of 9-OH-NME (mg) aPercentage of ILS (Increasing Life Span) values were determined from median survival times comparing treated and control group. bLDL/F: LDL/Free median survival time; values were determined by dividing the median survival time ofthe OL-NME-LDL group by the median survival time of mice administered with the equivalent dose of free 9-OH-NME. cSignificant at the P < 0.05 level against free 9-OH-NME correspondant dose and schedule experiment. dSignificant at the P<0.01 level against free 9-OH-NME correspondant dose and schedule experiment. eNonsignificant against free 9-OH-NME and significant at the level of P < 0.05 against OL-NME-LDL for the same schedule experiment. %,] range of deaths.
Table IV Antitumoral activity of free 9-OH-NME and OL-NME-LDL complex in subcutaneous Melanoma B16 bearing CD57BL/6J mice. Mice were given injection i.v. ofthe indicated samples 24 h post s.c. implantation of the Melanoma B16 tumour. OL-NME was incorporated in the LDL as described under Materials and methods. Drug doses are expressed in terms of 9-OH-NME ( ._
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Subsequent studies investigated the efficacy of free 9-OH-NME and OL-NME-LDL complex in the B16 melanoma subcutaneous tumour model after intravenous injection (i.v.) of the drugs (Table IV) . Administration of 9-OH-NME as well as of the OL-NME-LDL complex at doses of between 4 and 13.5 mg kg-' on days 1, 3, 5 after the tumour injection did not result in increased survival. The Day 1 to Day 5 schedule of injection, with a total dose of 10mgkg-', increased the antitumour activity of the OL-NME-LDL complex resulting in an ILS value of 45% (LDL/free median survival time value of 1.52). In the same experimental conditions free 9-OH-NME was completely ineffective (ILS value of -2%).
Discussion
We report a technique to prepare a lipophilic ellipticine derivative-LDL complex (Samadi-Baboli et al., 1989; Samadi-Baboli et al., 1990) and its efficiency on the cytotoxicity against cancer cell lines. However, the incorporation level of the OL-NME into the LDL has limited us in the studies of the antitumoural activity of the complex. Here we describe a procedure for the production of stable micro emulsions containing OL-NME and triglyceride in order to improve the incorporation of the drug into LDL. Addition of albumin to the LDL micro emulsion incubation increases fusion between the particles. These results suggest that a specific interaction or fusion between LDL and micro emulsions in the presence of albumin facilitates the incorporation of OL-NME into LDL. The optimisation of the procedure leads to increase the incorporation of OL-NME molecules into an LDL particle by more than 5-fold (70 vs 400) without significant modification the LDL particle size. (Morton et al., 1983; Eisenberg et al., 1985; Dullaart et al., 1987) . It was important to determine the ability of synthetic lipophilic compounds (OL-NME) (Mahley et al., 1977) . Consequently, it may be predicted that if the receptor mechanism operates in vivo, CHD treatment of LDL should delay its clearance from the plasma to an extent which is totally dependent on the activity of the receptor pathway. By comparing the clearance rates of native and CHD treated LDL, it was hoped to determine the receptor-mediated fractional catabolism of native LDL and of the OL-NME-LDL complex. The specific Fractional Catabolic Rate of native LDL (0.72 pool/day) is similar to that of OL-NME-LDL (0.70 pool/day). These values are in accordance with Shepherd et al. (1980) . Several other methods have been described for the incorporation of lipophilic cytotoxic drug into LDL (see Shaw et al., 1988, for targeting could lead to increased exposure of OL-NME to the tumour and consequently, increase the antitumour efficacy.
The OL-NME-LDL complex exerts therapeutic activity in vivo after i.v. injection in B16 melanoma-bearing mice. It must be remembered, however, that this study has been performed with human LDL. Even if human LDL is recognised by the animal's receptor and particularly by the B16 melanoma tumour (Lombardi et al., 1988) Interestingly, daily fractional doses are more effective than single injection. This could be explained, partly by the fact that the uptake of LDL by the receptor pathway is a saturable process and partly by the fact that a high level of LDL cholesterol could down-regulate the expression of the LDL receptor (Brown & Goldstein, 1986 Abbreviations: 9-OH-NME, 9-hydroxy-N2-methyl ellipticinium acetate; OL-NME, 9-oleoyloxy-N2-methyl ellipticinium oleate; LDL, low density lipoprotein; VLDL, very low density lipoprotein; HDL, high density lipoprotein; LPDS, lipoprotein-deficient serum; HPLC, high-performance liquid chromatography; TG, triacyl glycerol; PC, phosphatidyl choline; PS, phosphatidyl serine; Sphin, spingomyelin; Ch, cholesterol; BSA, bovine serum albumin; i.v., intravenous; i.p., intraperitoneal; s.c., subcutaneous.
